Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multicenter, Safety and Efficacy Phase II/III Study of PRL3-Zumab in Solid Tumor Patients

NCT07290088 is registered in ClinicalTrials.gov with Intra-IMMUSG Pte Ltd as lead sponsor.

NCT NCT07290088
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07290088 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multicenter, Safety and Efficacy Phase II/III Study of PRL3-Zumab in Solid Tumor Patients
Lead sponsor
Intra-IMMUSG Pte Ltd
Phase
Phase 2/3
Overall status
Recruiting
Start date
January 9, 2023
Completion date
December 31, 2026
Enrollment
52 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid cancers